Nicki Vasquez - 29 Jan 2024 Form 4 Insider Report for SUTRO BIOPHARMA, INC. (STRO)

Role
CHIEF PORT. STRAT & ALNCE OFCR
Signature
/s/ Edward C. Albini as attorney-in-fact for Nicki Vasquez
Issuer symbol
STRO
Transactions as of
29 Jan 2024
Net transactions value
-$66,035
Form type
4
Filing time
31 Jan 2024, 16:23:31 UTC
Previous filing
13 Jul 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction STRO Common Stock Sale $60,925 -12,185 -49% $5.00 12,803 29 Jan 2024 Direct F1
transaction STRO Common Stock Options Exercise $0 +2,500 +20% $0.000000 15,303 29 Jan 2024 Direct
transaction STRO Common Stock Tax liability $5,110 -1,024 -6.7% $4.99 14,279 29 Jan 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STRO Restricted Stock Unit (RSU) Options Exercise $0 -2,500 -100% $0.000000* 0 29 Jan 2024 Common Stock 2,500 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was entered into pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 29, 2023.
F2 Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person.
F3 Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.
F4 The RSUs vest as to 1/4th of the total shares annually beginning on January 29, 2021, subject to the reporting person's provision of service to the issuer on each vesting date.